ABIO (ARCA Bio) צמיחת רווח למניה בשנה הנוכחית

ARCA Biopharma (ABIO) fully outsources its production and research to external laboratories. The volatility of annual earnings per share reflects the dynamics of this process, with 0.00 serving as the current metric level. The firm's efficiency is based on the genetic selection of therapy. However, the absence of commercial products makes its capitalization dependent on cash reserves and the prospects of future patents.
פילוחי מדדים פיננסיים ומדדי שוק עבור ARCA Bio (ABIO)

ARCA Biopharma (ABIO) operates by depleting existing reserves in the absence of operating income, making profit analysis critical. This metric measures the year-over-year dynamics of earnings per share, identifying systemic degradation or growth in business efficiency. The negative trend in the company's annual net income growth per share signals a risk of asset impairment and potential capital freeze.